CHD7 and CHARGE syndrome: Depending on the clinical selection, 60–90% of the individuals suspected for CHARGE syndrome have de novo, heterozygous mutations in the CHD7 (Chromodomain helicase DNA-binding protein 7, MIM#608892) gene (Vissers et al., 2004; Bilan et al., 2012; Janssen et al., 2012).